Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
This study will test the hypothesis that noninvasive ventilation (NIV) as prescribed in current medical practice for use in amyotrophic Lateral Sclerosis (ALS) patients fails to deliver adequate breathing support over a night of use in the patient's home. ALS patients who come to the ALS Center for their routine 3 month follow up exam and are currently using NIV will be asked to complete questionnaires regarding their quality of sleep, quality of life and general level of function, and to undergo a home sleep study, using a safe, comfortable and reliable breathing monitoring system during a night of sleep. If the questionnaires or the sleep study show failure of the breathing device, the investigators will work with the patient to fix the problem and then offer a second study to make sure that the changes were helpful. The results of this study may help to develop subsequent studies and to improve the guidelines used for care of ALS patients.
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prevalence and Severity of Nocturnal Oxygenation and Ventilation Failure in Patients With Amyotrophic Lateral Sclerosis Using Noninvasive Ventilation|
- Tolerance of bilevel PAP [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]The ALS Functional Rating Scale — Revised (ALSFRS-R) will be administered to measure tolerance.
- Score on Epworth Sleepiness Scale [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]Objective evidence of nocturnal sleep-disordered breathing on the bilevel PAP will be measured.
|Study Start Date:||May 2007|
|Study Completion Date:||June 2011|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's Disease", is a fatal disorder that causes breathing failure due to progressive weakness of the muscles of breathing. Breathing assist devices known as noninvasive ventilation (NIV) are offered to ALS patients when their breathing function worsens. These devices deliver breathing assistance via a mask on the nose or nose and mouth, and are thought to be particularly important to be used during sleep, when breathing often becomes more shallow and irregular. However, although these devices have become the standard of therapy in ALS patients once their lung function worsens, it remains unclear how effective these devices actually are when a patient is sleeping, partly because of the practical difficulties in applying the device properly and keeping it applied throughout the sleep period, and partly because they are most commonly prescribed without objective evidence regarding how much breathing support the patient needs as the disease progresses and the breathing muscles weaken further.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00537641
|United States, New York|
|Eleanor and Lou Gehrig ALS/MDA Center at Columbia University|
|New York, New York, United States, 10032|
|Principal Investigator:||Robert Basner, MD||Columbia University|